Gender-Based Differences by Age Range in Patients Hospitalized with COVID-19: A Spanish Observational Cohort Study
Overview
Authors
Affiliations
There is some evidence that male gender could have a negative impact on the prognosis and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The aim of the present study was to compare the characteristics of coronavirus disease 2019 (COVID-19) between hospitalized men and women with confirmed SARS-CoV-2 infection. This multicenter, retrospective, observational study is based on the SEMI-COVID-19 Registry. We analyzed the differences between men and women for a wide variety of demographic, clinical, and treatment variables, and the sex distribution of the reported COVID-19 deaths, as well as intensive care unit (ICU) admission by age subgroups. This work analyzed 12,063 patients (56.8% men). The women in our study were older than the men, on average (67.9 vs. 65.7 years; < 001). Bilateral condensation was more frequent among men than women (31.8% vs. 29.9%; = 0.007). The men needed non-invasive and invasive mechanical ventilation more frequently (5.6% vs. 3.6%, < 0.001, and 7.9% vs. 4.8%, < 0.001, respectively). The most prevalent complication was acute respiratory distress syndrome, with severe cases in 19.9% of men ( < 0.001). In men, intensive care unit admission was more frequent (10% vs. 6.1%; < 0.001) and the mortality rate was higher (23.1% vs. 18.9%; < 0.001). Regarding mortality, the differences by gender were statistically significant in the age groups from 55 years to 89 years of age. A multivariate analysis showed that female sex was significantly and independently associated with a lower risk of mortality in our study. Male sex appears to be related to worse progress in COVID-19 patients and is an independent prognostic factor for mortality. In order to fully understand its prognostic impact, other factors associated with sex must be considered.
Ramos-Rincon J, Sanchez-Paya J, Gonzalez-De-La-Aleja P, Rodriguez-Diaz J, Merino E Front Public Health. 2025; 13:1488283.
PMID: 39980912 PMC: 11841506. DOI: 10.3389/fpubh.2025.1488283.
Opalska A, Gardarsdottir H, Kwa M, Wojkowska-Mach J, Sabate M, Ballarin M Eur J Clin Pharmacol. 2024; 80(10):1581-1589.
PMID: 39017693 PMC: 11393094. DOI: 10.1007/s00228-024-03726-1.
Redondo-Calvo F, Padin J, Ramon Munoz-Rodriguez J, Serrano-Oviedo L, Lopez-Juarez P, Porras Leal M Eur J Clin Invest. 2022; 52(6):e13776.
PMID: 35342931 PMC: 9111659. DOI: 10.1111/eci.13776.
An Early Th1 Response Is a Key Factor for a Favorable COVID-19 Evolution.
Gil-Etayo F, Garcinuno S, Utrero-Rico A, Cabrera-Marante O, Arroyo-Sanchez D, Mancebo E Biomedicines. 2022; 10(2).
PMID: 35203509 PMC: 8869678. DOI: 10.3390/biomedicines10020296.
Pagano M, Peruzzu D, Busani L, Pierdominici M, Ruggieri A, Antinori A Biol Sex Differ. 2021; 12(1):63.
PMID: 34809704 PMC: 8607227. DOI: 10.1186/s13293-021-00407-x.